Wed, Apr 16, 2014, 12:24 AM EDT - U.S. Markets open in 9 hrs 6 mins

Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • market_ace market_ace Sep 4, 2012 9:33 AM Flag

    Opens down 30 cents on no news?

    One last short ploy here to get shares before the upcoming conferences / news period?

    good luck -
    ace

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For years now, I have never seen a nice pop because of a CRIS conference presentation. You will recall , the first day after FDA approvel of Ev, price shot to 5.60 range, then was rammed down to the $4's, then it struggled back to mid $5, and now another ram down.So I do not hold out much hope for upcoming conferences announcments; hope I am surprised. We saw a recent article saying [in layman's language] that a CRIS combo "beat back breast cancer". . . and, nothing?!?! I am still long for as long as it takes for CRIS results to overpower the vultures. I have read that shorting good news on a bniotech is commonly done because the news pop usually does fade back before the L/T climb. WTH, we're not even getting any news pops. I have also read a leading biostock investment letter saying that CRIS gets too little royalty $$$ to make Ev approval exciting news. I say again, CRIS needs a major event to pop pps; maybe even 2 major events coming close together. I firmly believe that will happen, and then the mm's, hedge funds, shorters and day traders will give this stock a history making POP. GLTA, going to try Google Finance now.

    • Are we looking at another year of this before the big dogs are convinced this company can make money consistantly? Does the Debt continue to rise? The income dissapoint? Certainly the pipe line doesn't dissapoint. There just isn't any love out there for this stock, at least from those that can really push it north of $5 for good. I, for one, did not think I would ever see it back below $4. What a shame.

      Sentiment: Hold

    • There was an article that came out and was picked up by USA Today regarding SU2C.

      The trial looked at the usage of the standard drug Gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer. About half the patients showed reductions in tumor size, and about 50 percent lived at least a year, compared with the average of six months typical of this group.

      "For the first time, we have two-year survivors. And historically, we had no one that lived that long," Von Hoff said

      Sentiment: Buy

      • 2 Replies to jmnatt
      • Looks like 68K shares traded in the first minute today between the open of $4.27 and the low price of $4.11. Not sure what to make of that, but I hope it wasn't someone's brand new stop loss thrown out there.

        I've said it before, and I'll say it again -- a little insider buying at these levels would go a long way towards ending this kind of monkey business, if that's what this is. It certainly does smack of short desperation with SU2C and several conferences coming up.

        good luck -
        ace

        Sentiment: Strong Buy

      • Here is excerpt from article

        Along with conducting the Stand Up to Cancer study, researchers at the Piper cancer center are:

        Combining the anti-malarial drug hydroxychloroquine, which laboratory studies showed induces death of cancer cells, with a chemotherapy regimen of Gemcitabine plus Abraxane in patients with advanced pancreatic cancer.

        Examining tumor molecular profiles in patients who have had surgery for pancreatic cancer.

        Using the drug Erivedge, a Hedgehog pathway inhibitor, to break through the tough coating surrounding the cancer so a drug can enter and kill the cancer cells.

        The center participates in a wide range of other pancreatic-cancer studies. Results of another clinical trial involving 67 patients that were published last year in the Journal of Clinical Oncology showed promise.

        The trial looked at the usage of the standard drug Gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer. About half the patients showed reductions in tumor size, and about 50percent lived at least a year, compared with the average of six months typical of this group.

        "For the first time, we have two-year survivors. And historically, we had no one that lived that long," Von Hoff said.

    • Wasn't there some 'old pro' on here recently postulating that 'manipulation' is a fantasy indulged in by the uninformed? Reminds me of the old line about convincing people he didn't exist being the Devil's greatest trick.

    • An entire weeks worth of grinding gains wiped out before the new week even begins

 
CRIS
2.32+0.03(+1.31%)Apr 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.